(NASDAQ:KURA),(TSE:4151.T), – 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R […]

(NasdaqGM:CRVS), Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights

100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) — March Biosciences (March Bio), an clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced positive interim clinical data from its ongoing Phase 2 trial of MB-105

AVTR Investors Have Opportunity to Lead Avantor, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire December 08, 2025 LOS ANGELES, Dec. 08, 2025 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avantor, Inc. (“Avantor” or “the Company”) (NYSE: AVTR) for

Lifestyle Expert Anna De Souza Shares This Year's Top Toys and Trending Holiday Gift Ideas for Kids on YourUpdateTV Holiday Toy Must-Haves: The Expert's Guide with Picks from Target GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Holiday toy shopping can feel like a big task, especially as wish lists seem

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial GlobeNewswire December 08, 2025 Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL,

March Biosciences Presents Positive Interim Clinical Data from Phase 2 Trial of MB-105 CD5 CAR-T Cell Therapy at ASH 2025 Annual Meeting GlobeNewswire December 08, 2025 100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) — March Biosciences (March Bio), an

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI(TM) (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML GlobeNewswire December 08, 2025 – 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of

AQUAPASS, a medical technology company pioneering non-invasive fluid management solutions, has received marketing approval for the AQUAPASS System in Israel, marking a major milestone in bringing its novel therapy to patients suffering from fluid overload. https://mma.prnewswire.com/media/2840669/AQUAPASS_Inc_Logo.jpg As part of the initial rollout, AQUAPASS will begin commercial deployment in selected medical centers across Israel, working closely

Oviedo, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) — Dandy(R) Celery is back with its biggest annual promotion, the 10th anniversary of 'Dip It 2 Win It'! Grown by Duda Farm Fresh Foods, a family-owned company with nearly 100 years of farming heritage and a reputation for innovation in celery, Dandy(R) delivers the crisp, fresh flavor